These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 10329064)

  • 1. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.
    Eur Heart J; 1999 May; 20(10):725-41. PubMed ID: 10329064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
    Heart Protection Study Collaborative Group
    Lancet; 2002 Jul; 360(9326):7-22. PubMed ID: 12114036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
    Collins R; Armitage J; Parish S; Sleigh P; Peto R;
    Lancet; 2003 Jun; 361(9374):2005-16. PubMed ID: 12814710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    Brown BG; Zhao XQ; Chait A; Fisher LD; Cheung MC; Morse JS; Dowdy AA; Marino EK; Bolson EL; Alaupovic P; Frohlich J; Albers JJ
    N Engl J Med; 2001 Nov; 345(22):1583-92. PubMed ID: 11757504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.
    Heart Protection Study Collaborative Group
    Lancet; 2002 Jul; 360(9326):23-33. PubMed ID: 12114037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
    Collins R; Armitage J; Parish S; Sleight P; Peto R;
    Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.
    Heart Protection Study Collaborative Group
    J Vasc Surg; 2007 Apr; 45(4):645-654; discussion 653-4. PubMed ID: 17398372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
    Heart Protection Study Collaborative Group
    Lancet; 2011 Dec; 378(9808):2013-2020. PubMed ID: 22115874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
    Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.
    Keech A; Collins R; MacMahon S; Armitage J; Lawson A; Wallendszus K; Fatemian M; Kearney E; Lyon V; Mindell J
    Eur Heart J; 1994 Feb; 15(2):255-69. PubMed ID: 8005129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].
    Heart Protection Study Collaborative Group
    BMC Med; 2005 Mar; 3():6. PubMed ID: 15771782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
    ; Armitage J; Bowman L; Wallendszus K; Bulbulia R; Rahimi K; Haynes R; Parish S; Peto R; Collins R
    Lancet; 2010 Nov; 376(9753):1658-69. PubMed ID: 21067805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
    Sharp Collaborative Group
    Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
    Baigent C; Landray MJ; Reith C; Emberson J; Wheeler DC; Tomson C; Wanner C; Krane V; Cass A; Craig J; Neal B; Jiang L; Hooi LS; Levin A; Agodoa L; Gaziano M; Kasiske B; Walker R; Massy ZA; Feldt-Rasmussen B; Krairittichai U; Ophascharoensuk V; Fellström B; Holdaas H; Tesar V; Wiecek A; Grobbee D; de Zeeuw D; Grönhagen-Riska C; Dasgupta T; Lewis D; Herrington W; Mafham M; Majoni W; Wallendszus K; Grimm R; Pedersen T; Tobert J; Armitage J; Baxter A; Bray C; Chen Y; Chen Z; Hill M; Knott C; Parish S; Simpson D; Sleight P; Young A; Collins R;
    Lancet; 2011 Jun; 377(9784):2181-92. PubMed ID: 21663949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
    Baigent C; Keech A; Kearney PM; Blackwell L; Buck G; Pollicino C; Kirby A; Sourjina T; Peto R; Collins R; Simes R;
    Lancet; 2005 Oct; 366(9493):1267-78. PubMed ID: 16214597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.
    Ballantyne CM; Olsson AG; Cook TJ; Mercuri MF; Pedersen TR; Kjekshus J
    Circulation; 2001 Dec; 104(25):3046-51. PubMed ID: 11748098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
    ; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W
    N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
    Mitropoulos KA; Armitage JM; Collins R; Meade TW; Reeves BE; Wallendszus KR; Wilson SS; Lawson A; Peto R
    Eur Heart J; 1997 Feb; 18(2):235-41. PubMed ID: 9043839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.